Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective This study investigates the cost-effectiveness of betibeglogene autotemcel (‘beti-cel’; LentiGlobin for β-thalasse...

Full description

Bibliographic Details
Main Authors: Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Journal of Market Access & Health Policy
Subjects:
beta-thalassemia
economic evaluation
gene therapy
Online Access:http://dx.doi.org/10.1080/20016689.2021.1922028

Internet

http://dx.doi.org/10.1080/20016689.2021.1922028

Similar Items